Artron Laboratories Inc. Announces Q1 2026 EPS of NT$0.28

Key facts

  • Artron Laboratories Inc. Announces Q1 2026 EPS of NT$0.28
  • Artron Laboratories Inc. announced its Q1 2026 financial results, with EPS of NT$0.28, operating revenue of NT$88 million, and net income after tax of NT$17 million, reflecting steady business performance in the biotechnology and medical sector.
  • Source: PR Times
  • Date: March 1, 2026

Direct answer

Artron Laboratories Inc. announced its Q1 2026 financial results, with EPS of NT$0.28, operating revenue of NT$88 million, and net income after tax of NT$17 million, reflecting steady business performance in the biotechnology and medical sector.

Citation
Artron Laboratories Inc. Announces Q1 2026 EPS of NT$0.28 (March 1, 2026), PR Times
Source
PR Times
Date
March 1, 2026
Artron Laboratories Inc. announced its Q1 2026 financial results, with EPS of NT$0.28, operating revenue of NT$88 million, and net income after tax of NT$17 million, reflecting steady business performance in the biotechnology and medical sector.
その他NQ 0/100出典:PR Times

📋 Article Processing Timeline

  • 📰 Published: March 1, 2026 at 09:00
  • 🔍 Collected: May 14, 2026 at 08:00 (1775h 0m after Published)
  • 🤖 AI Analyzed: May 14, 2026 at 08:11 (10 min after Collected)
## Artron Laboratories Inc. Q1 2026 Financial Results Express Report

Company Code: 4133
Company Name: Artron Laboratories Inc.
Industry: Biotechnology and Medical Industry
Fiscal Year/Quarter: Q1 2026
Basic Earnings Per Share (EPS): NT$0.28
Operating Revenue: NT$88 million
Net Income After Tax: NT$17 million

FAQ

What are the key facts in this article?

Artron Laboratories Inc. announced its Q1 2026 financial results, with EPS of NT$0.28, operating revenue of NT$88 million, and net income after tax of NT$17 million, reflecting steady business performance in the biotechnology and medical sector.

What is the direct answer?

Artron Laboratories Inc. announced its Q1 2026 financial results, with EPS of NT$0.28, operating revenue of NT$88 million, and net income after tax of NT$17 million, reflecting steady business performance in the biotechnology and medical sector.

What is the source and date?

PR Times: https://openapi.twse.com.tw/financial/twse-fin-4133-2026Q1 | March 1, 2026